Back to resultsOcular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome (RETINO2018)
Primary Purpose
Retinoblastoma
Status
Recruiting
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Melphalan or Melphalan + Topotecan
etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy
Carboplatin administered on Day 1
Thermotherapy (local treatment)
Cryotherapy (local treatment)
Iodine-125 plaques (local treatment)
Intravitreal Melphalan chemotherapy injections (local treatment)
Sponsored by
About this trial
This is an interventional treatment trial for Retinoblastoma focused on measuring Pediatric, Ocular conservative treatment in retinoblastoma
Eligibility Criteria
Inclusion Criteria:
Overall study inclusion criteria:
- Newly diagnosed retinoblastoma (RB).
- Retinoblastoma with at least one eye eligible for conservative management.
- Patients likely to be compliant with the study requirements and visits, including late follow-up.
- Patients not previously treated with chemotherapy or radiotherapy for this or any other cancer.
- Patients with no contraindication to the proposed treatments.
- Informed consent signed by parents or legal representative.
- French Social Security System coverage.
Study 1 inclusion criteria:
8.1. Children aged from 6 months to 6 years. 9. Retinoblastoma in at least one eye, deemed manageable with IAC in one side and without IV chemotherapy:
- Unilateral Retinoblastoma classified as group B, C (if vitreous seeds < 3 mm), D or E with no invasion of the anterior segment, and without massive tumor of more than 2/3 of the eye, eligible for conservative management, or
- Bilateral Retinoblastoma but with very unbalanced lesions between the two eyes: one eye group D or E without invasion of the anterior segment or massive tumor of more than 2/3 of the eye, eligible for IAC, and the other eye eligible for local treatment only (without IAC).
Study 2 inclusion criteria:
8.2. Retinoblastoma eligible for conservative management although not manageable with IAC:
- Unilateral Retinoblastoma in children below 6 months of age, classified as Group A, B, C or D, with or without vitreous seeding, compatible with conservative management, or
- Bilateral Retinoblastoma classified as group A, B, C D, or E without invasion of the anterior segment, and/or massive tumors of more than 2/3 of the eye and eligible for conservative management.
Exclusion Criteria:
Overall study non-inclusion criteria:
RB not eligible for conservative management :
- Extra-ocular extension of the disease, or
- Group E eyes with invasion of the anterior segment, and/or massive tumors of more than 2/3 of the eye.
- Patient older than 6 years of age.
- Patients with another associated disease contra indicating systemic chemotherapy.
- Previously treated retinoblastoma by chemotherapy.
- Patients already treated for another malignant disease.
- Patient with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- Patients whose parents have not accepted the treatment regimen after explanation of it.
- Contraindication to study drug mentioned in SmPC (Summary of Products Characteristics) of the study drugs.
Inclusion in another experimental anti-cancer drug therapy.
Study 1 non-inclusion criteria:
- Any contraindication or concomitant disease that would preclude the Study 1 treatment procedure and could delay treatment.
These patients should be eligible for Study 2.
Sites / Locations
- La Reunion - Chr Felix GuyonRecruiting
- Amiens ChuRecruiting
- Angers ChuRecruiting
- BESANCON CHU Hopital Jean MinjozRecruiting
- Bordeaux ChuRecruiting
- BREST CHRU Hopital MorvanRecruiting
- CAEN CHURecruiting
- CHU ESTAING Centre Régional de Cancérologie et Therapie Cellulaire Pediatrique (CRCTCP)Recruiting
- DIJON CHU Hopital François MitterandRecruiting
- Grenoble ChuRecruiting
- LILLE Centre Oscar LambretRecruiting
- Limoges ChuRecruiting
- LYON Centre Léon BérardRecruiting
- Marseille ChuRecruiting
- MONTPELLIER CHU Hopital Arnaud De VilleneuveRecruiting
- NANTES CHU Hopital Mere-EnfantRecruiting
- NICE CHU Hopital Archet 2Recruiting
- Institut CurieRecruiting
- PARIS Fondation Ophtalmologique Adolphe de RothschildRecruiting
- Poitiers ChuRecruiting
- Reims ChuRecruiting
- Rennes ChuRecruiting
- Rouen ChuRecruiting
- Saint Etienne ChuRecruiting
- Strasbourg ChuRecruiting
- Toulouse ChuRecruiting
- TOURS CHU Hopital ClochevilleRecruiting
- Nancy ChuRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Study 1: Melphalan or Melphalan + Topotecan
Study 2: Etoposide, carboplatin and vincristine
Arm Description
Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
Neoadjuvant chemotherapy involves 2 to 6 cycles of combined etoposide, carboplatin and vincristine in association with ophthalmologic treatments.
Outcomes
Primary Outcome Measures
Study 1: Rate of eye preservation
Rate of eye preservation in the 2 treatments' arms
Visual function
Percentage of patients with major, mild or no impairment of visual function according to WHO criteria, i.e. normal bilateral visual acuity (≥ 6/10) or mild bilateral visual impairment (3/10 to 5/10) according to tumor location and extension
Secondary Outcome Measures
Ocular toxicity
Percentage of patients with at least one grade-3 or -4 toxicity (CTCAE v. 5.0)
Systemic toxicity
Rate of specific grade 3-4 toxicity (CTCAE v. 5.0)
Relapse
Percentage of patients with relapse within 24 months after inclusion, broken down into: Local relapse, Extra-ocular relapse
Second malignant tumor
Percentage of patients with second malignant tumor within 24 months after study inclusion
Additional assessment of visual function
Additional assessment of visual function at follow-up: Percentage of patients at each of the four levels of visual acuity according to WHO criteria
Retinal assessment
Optical Coherence Tomography (OCT) and Optical Coherence Tomography-Angiography (OCT-A) measures on retina
Integration at school
Rate of children able to attend the common primary school : without specific help or with the help of a dedicated person and/or with specific features to facilitate reading and writing
Full Information
NCT ID
NCT04681417
First Posted
December 17, 2020
Last Updated
April 24, 2023
Sponsor
Institut Curie
Collaborators
Fondation Rothschild Paris
1. Study Identification
Unique Protocol Identification Number
NCT04681417
Brief Title
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
Acronym
RETINO2018
Official Title
Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 25, 2021 (Actual)
Primary Completion Date
January 20, 2035 (Anticipated)
Study Completion Date
January 20, 2036 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Curie
Collaborators
Fondation Rothschild Paris
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients:
Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic or local ophthalmological treatment without IV chemotherapy.
Detailed Description
Primary objective of the studies:
Study 1: To evaluate the efficacy of IAC in term of local control of the disease in patients eligible for IAC (randomized phase II study);
Study 2: To assess the visual function, based on World Health Organization (WHO) criteria, in patients eligible for other conservative treatments (IV chemotherapy in association with local ophthalmologic trématent or local ophthalmological treatment without IV chemotherapy; this is a minimally invasive interventional study).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retinoblastoma
Keywords
Pediatric, Ocular conservative treatment in retinoblastoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
225 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Study 1: Melphalan or Melphalan + Topotecan
Arm Type
Experimental
Arm Description
Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
Arm Title
Study 2: Etoposide, carboplatin and vincristine
Arm Type
Other
Arm Description
Neoadjuvant chemotherapy involves 2 to 6 cycles of combined etoposide, carboplatin and vincristine in association with ophthalmologic treatments.
Intervention Type
Drug
Intervention Name(s)
Melphalan or Melphalan + Topotecan
Other Intervention Name(s)
Alkeran, Topotecan Accord; Topotecan Hospira chemotherapy
Intervention Description
IAC: 2-6 cycles every 1 month (number based on the local tumor evolution), performed using radio-guided catheterization and delivery at the ostium of the ophthalmic artery, in neuroradiology operating room, and under General Anesthesia (GA). IAC will be administered at the Fondation Rothschild Hospital in collaboration with the Interventional Neuroradiology team.
Intervention Type
Drug
Intervention Name(s)
etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy
Other Intervention Name(s)
etoposide, carboplatin and vincristine chemotherapy
Intervention Description
2 to 6 cycles of combined etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy : thermotherapy and/or cryotherapy and/or iodine-125 plaques and/or intravitreal chemotherapy injections
Intervention Type
Drug
Intervention Name(s)
Carboplatin administered on Day 1
Other Intervention Name(s)
platinum-based chemotherapy
Intervention Description
Chemothermotherapy : Intravenous injection by carboplatin
Intervention Type
Device
Intervention Name(s)
Thermotherapy (local treatment)
Other Intervention Name(s)
Thermotherapy after carboplatin administered on Day 1
Intervention Description
Thermotherapy after carboplatin administered on Day 1
Intervention Type
Device
Intervention Name(s)
Cryotherapy (local treatment)
Intervention Description
Cryotherapy (local treatment)
Intervention Type
Device
Intervention Name(s)
Iodine-125 plaques (local treatment)
Intervention Description
Iodine-125 plaques (local treatment)
Intervention Type
Drug
Intervention Name(s)
Intravitreal Melphalan chemotherapy injections (local treatment)
Intervention Description
Intravitreal Melphalan chemotherapy injections (local treatment)
Primary Outcome Measure Information:
Title
Study 1: Rate of eye preservation
Description
Rate of eye preservation in the 2 treatments' arms
Time Frame
24 months after randomization
Title
Visual function
Description
Percentage of patients with major, mild or no impairment of visual function according to WHO criteria, i.e. normal bilateral visual acuity (≥ 6/10) or mild bilateral visual impairment (3/10 to 5/10) according to tumor location and extension
Time Frame
when patient is 6 years old and at least 24 months of follow-up after study inclusion
Secondary Outcome Measure Information:
Title
Ocular toxicity
Description
Percentage of patients with at least one grade-3 or -4 toxicity (CTCAE v. 5.0)
Time Frame
Up to 24 months after inclusion in the study
Title
Systemic toxicity
Description
Rate of specific grade 3-4 toxicity (CTCAE v. 5.0)
Time Frame
Up to 24 months after inclusion in the study
Title
Relapse
Description
Percentage of patients with relapse within 24 months after inclusion, broken down into: Local relapse, Extra-ocular relapse
Time Frame
within 24 months after inclusion
Title
Second malignant tumor
Description
Percentage of patients with second malignant tumor within 24 months after study inclusion
Time Frame
24 months after study inclusion
Title
Additional assessment of visual function
Description
Additional assessment of visual function at follow-up: Percentage of patients at each of the four levels of visual acuity according to WHO criteria
Time Frame
In the year patients turn 6 years of age and at least 24 months of treatment
Title
Retinal assessment
Description
Optical Coherence Tomography (OCT) and Optical Coherence Tomography-Angiography (OCT-A) measures on retina
Time Frame
In the year patients turn 6 years of age and at least 24 months of treatment
Title
Integration at school
Description
Rate of children able to attend the common primary school : without specific help or with the help of a dedicated person and/or with specific features to facilitate reading and writing
Time Frame
In the year patients turn 6 years of age and at least 24 months of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Overall study inclusion criteria:
Newly diagnosed retinoblastoma (RB).
Retinoblastoma with at least one eye eligible for conservative management.
Patients likely to be compliant with the study requirements and visits, including late follow-up.
Patients not previously treated with chemotherapy or radiotherapy for this or any other cancer.
Patients with no contraindication to the proposed treatments.
Informed consent signed by parents or legal representative.
French Social Security System coverage.
Study 1 inclusion criteria:
8.1. Children aged from 6 months to 6 years. 9. Retinoblastoma in at least one eye, deemed manageable with IAC in one side and without IV chemotherapy:
Unilateral Retinoblastoma classified as group B, C (if vitreous seeds < 3 mm), D or E with no invasion of the anterior segment, and without massive tumor of more than 2/3 of the eye, eligible for conservative management, or
Bilateral Retinoblastoma but with very unbalanced lesions between the two eyes: one eye group D or E without invasion of the anterior segment or massive tumor of more than 2/3 of the eye, eligible for IAC, and the other eye eligible for local treatment only (without IAC).
Study 2 inclusion criteria:
8.2. Retinoblastoma eligible for conservative management although not manageable with IAC:
Unilateral Retinoblastoma in children below 6 months of age, classified as Group A, B, C or D, with or without vitreous seeding, compatible with conservative management, or
Bilateral Retinoblastoma classified as group A, B, C D, or E without invasion of the anterior segment, and/or massive tumors of more than 2/3 of the eye and eligible for conservative management.
Exclusion Criteria:
Overall study non-inclusion criteria:
RB not eligible for conservative management :
Extra-ocular extension of the disease, or
Group E eyes with invasion of the anterior segment, and/or massive tumors of more than 2/3 of the eye.
Patient older than 6 years of age.
Patients with another associated disease contra indicating systemic chemotherapy.
Previously treated retinoblastoma by chemotherapy.
Patients already treated for another malignant disease.
Patient with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Patients whose parents have not accepted the treatment regimen after explanation of it.
Contraindication to study drug mentioned in SmPC (Summary of Products Characteristics) of the study drugs.
Inclusion in another experimental anti-cancer drug therapy.
Study 1 non-inclusion criteria:
Any contraindication or concomitant disease that would preclude the Study 1 treatment procedure and could delay treatment.
These patients should be eligible for Study 2.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Livia LUMBROSO LE ROUIC, MD
Phone
+33(0)144324163
Email
livia.lumbroso-lerouic@curie.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Christine FOULON, PhD
Phone
+33(0)147111733
Email
drci.promotion@curie.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Livia LUMBROSO LE ROUIC, MD
Organizational Affiliation
Institut Curie
Official's Role
Principal Investigator
Facility Information:
Facility Name
La Reunion - Chr Felix Guyon
City
Saint-Denis
State/Province
La Réunion
ZIP/Postal Code
97405
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yves REGUERRE, MD
Phone
26(2)262905676
Email
yves.reguerre@chu-reunion.fr
First Name & Middle Initial & Last Name & Degree
Yves REGUERRE, MD
Facility Name
Amiens Chu
City
Amiens
ZIP/Postal Code
80054
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leslie ANDRY, MD
Phone
+33(0)322087650
Email
andry.leslie@chu-amiens.fr
First Name & Middle Initial & Last Name & Degree
Antoine GOURMEL, MD
Facility Name
Angers Chu
City
Angers
ZIP/Postal Code
49033
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabelle PELLIER, MD
Phone
+33(0)241353863
Email
ispellier@chu-angers.fr
First Name & Middle Initial & Last Name & Degree
Isabelle PELLIER, MD
Facility Name
BESANCON CHU Hopital Jean Minjoz
City
Besancon
ZIP/Postal Code
25030
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sébastien KLEIN, MD
Phone
+33(0)381219212
Email
sklein@chu-beancon.fr
First Name & Middle Initial & Last Name & Degree
Sébastien KLEIN, MD
Facility Name
Bordeaux Chu
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Céline DE BOUYN ICHER, MD
Phone
+33(0)557820434
Email
celine.icher@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Céline DE BOUYN ICHER, MD
Facility Name
BREST CHRU Hopital Morvan
City
Brest
ZIP/Postal Code
29609
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liana-Stéphania CARAUSU, MD
Phone
(+33) 02 98 22 37 70
Email
liana.carausu@chu-brest.fr
First Name & Middle Initial & Last Name & Degree
Liana-Stéphania CARAUSU, MD
Facility Name
CAEN CHU
City
Caen
ZIP/Postal Code
14033
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Damien BODET, MD
Phone
+33(0)231064488
Email
bodet-d@chu-caen.fr
First Name & Middle Initial & Last Name & Degree
Damien BODET, MD
Facility Name
CHU ESTAING Centre Régional de Cancérologie et Therapie Cellulaire Pediatrique (CRCTCP)
City
Clermont-Ferrand
ZIP/Postal Code
63003
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Justyna KANOLD, MD
Phone
(+33) 04 73 75 00 09
Email
jkanold@chu-clermontferrand.fr
First Name & Middle Initial & Last Name & Degree
Justyna KANOLD, MD
Facility Name
DIJON CHU Hopital François Mitterand
City
Dijon
ZIP/Postal Code
21079
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claire BRIANDET, MD
Phone
+33(0)380293601
Email
claire.briandet@chu-dijon.fr
First Name & Middle Initial & Last Name & Degree
Claire BRIANDET, MD
Facility Name
Grenoble Chu
City
Grenoble
ZIP/Postal Code
38045
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominique PLANTAZ, MD
Phone
+33(0)476765911
Email
dplantaz@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Dominique PLANTAZ, MD
Facility Name
LILLE Centre Oscar Lambret
City
Lille
ZIP/Postal Code
59037
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hélène SUDOUR BONNANGE, MD
Phone
+33(0)320295959
Email
h-sudour@o-lambret.fr
First Name & Middle Initial & Last Name & Degree
Hélène SUDOUR BONNANGE, MD
Facility Name
Limoges Chu
City
Limoges
ZIP/Postal Code
87042
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christophe PIGUET, MD
Phone
+33(0)555056801
Email
christophe.piguet@chu-limoges.fr
First Name & Middle Initial & Last Name & Degree
Christophe Christophe PIGUET, MD
Facility Name
LYON Centre Léon Bérard
City
Lyon
ZIP/Postal Code
69373
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
BENOIT DUMONT, MD
Email
benoit.dumont@ihope.fr
Phone
+33 (0)4 69 16 65 74
First Name & Middle Initial & Last Name & Degree
BENOIT DUMONT, MD
Facility Name
Marseille Chu
City
Marseille
ZIP/Postal Code
13385
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carole COZE, MD
Phone
+33(0)491386821
Email
carole.coze@ap-hm.fr
First Name & Middle Initial & Last Name & Degree
Carole COZE, MD
Facility Name
MONTPELLIER CHU Hopital Arnaud De Villeneuve
City
Montpellier
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas SIRVENT, MD
Phone
+33(0)467336519
Email
n-sirvent@chu-montpellier.fr
First Name & Middle Initial & Last Name & Degree
Nicolas SIRVENT, MD
Facility Name
NANTES CHU Hopital Mere-Enfant
City
Nantes
ZIP/Postal Code
44093
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
LECULEE THEBAUD Estelle, MD
Phone
+33(0)240083610
Email
estelle.thebaud@chu-nantes.fr
First Name & Middle Initial & Last Name & Degree
LECULEE THEBAUD Estelle, MD
Facility Name
NICE CHU Hopital Archet 2
City
Nice
ZIP/Postal Code
06202
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gwenaëlle DUHIL DE BENAZE, MD
Phone
+33(0)492036064
Email
duhildebenaze.g@chu-nice.fr
First Name & Middle Initial & Last Name & Degree
Gwenaëlle DUHIL DE BENAZE, MD
Facility Name
Institut Curie
City
Paris
ZIP/Postal Code
75005
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Livia LUMBROSO LE ROUIC, MD
Phone
+33(0)144324163
Email
livia.lumbroso-lerouic@curie.fr
First Name & Middle Initial & Last Name & Degree
Isabelle AERTS, MD
Phone
+33(0)144324333
Email
isabelle.aerts@curie.fr
First Name & Middle Initial & Last Name & Degree
LIvia LUMBROSO LE ROUIC, MD
Facility Name
PARIS Fondation Ophtalmologique Adolphe de Rothschild
City
Paris
ZIP/Postal Code
75019
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raphaël BLANC, MD
Phone
+33(0)148036828
Email
rblanc@for.paris
First Name & Middle Initial & Last Name & Degree
Raphaël BLANC, MD
Facility Name
Poitiers Chu
City
Poitiers
ZIP/Postal Code
86021
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frédéric MILLOT, MD
Phone
+33(0)549443078
Email
f.millot@chu-poitiers.fr
First Name & Middle Initial & Last Name & Degree
Frédéric MILLOT, MD
Facility Name
Reims Chu
City
Reims
ZIP/Postal Code
51092
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claire PLUCHART, MD
Phone
+33(0)326787515
Email
cpluchart@chu-reims.fr
First Name & Middle Initial & Last Name & Degree
Claire PLUCHART, MD
Facility Name
Rennes Chu
City
Rennes
ZIP/Postal Code
35056
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chloé PUISEUX, MD
Phone
+33(0)299265917
Email
chloe.puiseux@chu-rennes.fr
First Name & Middle Initial & Last Name & Degree
Chloé PUISEUX, MD
Facility Name
Rouen Chu
City
Rouen
ZIP/Postal Code
76000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cécile DUMESNIL DE MARICOURT, MD
Phone
+33(0)232888191
Email
cecile.dumesnil@chu-rouen.fr
First Name & Middle Initial & Last Name & Degree
Cécile DUMESNIL DE MARICOURT, MD
Facility Name
Saint Etienne Chu
City
Saint Etienne
ZIP/Postal Code
42055
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Louis STEPHAN, MD
Phone
+33(0)478828608
Email
j.louis.stephan@chu-st-etienne.fr
First Name & Middle Initial & Last Name & Degree
Jean-Louis STEPHAN, MD
Facility Name
Strasbourg Chu
City
Strasbourg
ZIP/Postal Code
67098
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Natacha ENTZ WERLE, MD
Phone
+33(0)388128396
Email
natacha.entz-werle@chu-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Natacha ENTZ WERLE, MD
Facility Name
Toulouse Chu
City
Toulouse
ZIP/Postal Code
31026
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne-Isabelle BERTOZZI-SALAMON, MD
Phone
+33(0)534558613
Email
bertozzi.ai@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Anne-Isabelle BERTOZZI-SALAMON, MD
Facility Name
TOURS CHU Hopital Clocheville
City
Tours
ZIP/Postal Code
37044
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascale BLOUIN, MD
Phone
+33(0)247474751
Email
p.blouin@chu-tours.fr
First Name & Middle Initial & Last Name & Degree
Pascale BLOUIN, MD
Facility Name
Nancy Chu
City
Vandoeuvre Les Nancy
ZIP/Postal Code
54500
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ludovic MANSUY, MD
Phone
+33(0)383154734
Email
lu.mansuy@chu-nancy.fr
First Name & Middle Initial & Last Name & Degree
Ludovic MANSUY, MD
12. IPD Sharing Statement
Learn more about this trial
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
We'll reach out to this number within 24 hrs